23868-15-7

Upstream product

• 67-56-1 methanol 
• 16524-23-5 N-p-tolyl-anthranilic acid 
• 17763-70-1 methyl 2-(trifluoromethylsulfonyloxy)benzoate 
• 106-49-0 p-toluidine 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 624-31-7 4-tolyl iodide 
• 134-20-3 2-carbomethoxyaniline 

Downstream Products

• 412018-30-5 Diphenyl-(2-p-toluidino-phenyl)-methanol 
• 99233-98-4 2-<(2-Acetylphenyl)(4-methylphenyl)amino>benzoesaeure-methylester 
• 23868-09-9 2-methoxy-2-thioxo-1-p-tolyl-1,2-dihydro-2λ⁵-benzo[d][1,3,2]thiazaphosphinin-4-one 
• 16524-23-5 N-p-tolyl-anthranilic acid 
• 104014-54-2 7-Methoxy-12-(4-methylphenyl)dibenzazocin-5(12H)-on 
• 104014-53-1 6-Methyl-12-(4-methylphenyl)dibenzazocin-5,7(6H,12H)-dion 
• 99233-90-6 12-(4-Methylphenyl)dibenzazocin-5,7(6H,12H)-dion 
• 104014-65-5 12-(4-Methyl-2-nitrophenyl)dibenzazocin-5,7(6H,12H)-dion 
• 104014-69-9 12-(2-Brom-4-methylphenyl)dibenzazocin-5,7(6H,12H)-dion 
• 104014-68-8 12-(2-Chlor-4-methylphenyl)dibenzazocin-5,7(6H,12H)-dion 
• 104014-60-0 7,12-Dihydro-7-hydroxy-7-methyl-12-(4-methylphenyl)dibenzazocin-5(6H)-on 
• 102023-92-7 10-(4-methylphenyl)acridin-9(10H)-one 
• 23857-25-2 2-methoxy-2-thioxo-1-p-tolyl-1,2-dihydro-2λ⁵-benzo[d][1,3,2]thiazaphosphinine-4-thione 

Relevant academic research and scientific papers

Sodium Butylated Hydroxytoluene: A Functional Group Tolerant, Eco-Friendly Base for Solvent-Free, Pd-Catalysed Amination

NaBHT (sodium 2,6-di-tert-butyl-4-methylphenolate), a strong, but hindered and lipophilic base, has been effectively paired with similarly lipophilic, high-reactivity Pd-NHC (N-heterocyclic carbene) catalysts to produce an ideal combination for performing

Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N -phenyl-aminobenzoates and their structure-activity relationships

Aldo-keto reductase 1C3 (AKR1C3; type 5 17β-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5α-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of 5α-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.

12-Organyldibenzazocine-5,7-diones

The title compounds 10, 23 are formed in low yields on treatment of 2,2'-organylimino-bisbenzoic acid esters 8 with methyllithium, but in high yields in the intramolecular ester condensation with sodium hydride of triarylamines 12, containing o-acetyl-, a